An updated systematic review and meta-analysis on the efficacy and tolerability of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes with moderate to severe chronic kidney disease:

SAGE Open Medicine

DevadaSingh-Franco¹ 

关键词: Meta-analysis;    sitagliptin;    linagliptin;    saxagliptin;    vildagliptin;    dipeptidyl peptidase-4 inhibitors;    chronic kidney disease;    dialysis;    type 2 diabetes mellitus;   

DOI  :  10.1177/2050312116659090

学科分类：医学（综合）

来源: Sage Journals

【 摘 要 】

Objective:This updated meta-analysis determines the effect of dipeptidyl peptidase-4 inhibitors on glycemic and tolerability outcomes in patients with type 2 diabetes mellitus and chronic kidney disease with glomerular filtration rate of ⩽60 mL/min or on dialysis.Methods:In all, 14 citations were identified from multiple databases. Qualitative assessments and quantitative analyses were performed.Results:There were 2261 participants, 49–79 years of age, 49% men and 44% Caucasians. In seven placebo-comparator studies, reduction in hemoglobin A1c at weeks 12–24 was 0.55% (95% confidence interval: −0.68 to −0.43), P < 0.00001). In three sulfonylurea-comparator studies, dipeptidyl peptidase-4 inhibitors did not significantly reduce hemoglobin A1c at weeks 52–54 (−0.15% (95% confidence interval: −0.32 to 0.02)). In one sitagliptin versus albiglutide study, albiglutide significantly reduced hemoglobin A1c in patients with moderate renal impairment (−0.51%). A similar reduction in hemoglobin A1c was seen with sit...

【 授权许可】

CC BY